Intensive ranibizumab treatment of AMD linked to vascular adverse events

  • July 30, 2014

Intensity of intravitreal ranibizumab treatment for age-related macular degeneration may be linked to vascular adverse events, but not to an increased risk of mortality, according to researchers.

The researchers conducted a meta-analysis of 11 randomized trials that comprised 6,596 patients with AMD. The trials selected compared systemic safety among varied intensities of ranibizumab (Lucentis, Genentech) treatment for AMD.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
More »
More »
  • Meeting News Coverage
  • OSN meeting
  • Kiawah Eye 2014
  • Read live onsite coverage from the Kiawah Eye meeting in Kiawah, S.C.
More »